Deferasirox therapy is associated with reduced mortality risk in a medicare population with myelodysplastic syndromesAmer M. Zeidan, Amy J. Davidoff, Carole Paley et al.|Journal of Comparative Effectiveness Research|2015Cited by 45
Lenalidomide performance in the real worldAmer M. Zeidan, Amy J. Davidoff, Steven D. Gore et al.|Cancer|2013Cited by 41
Patterns of erythropoiesis-stimulating agent use among Medicare beneficiaries with myelodysplastic syndromes and consistency with clinical guidelinesAmy J. Davidoff, Steven D. Gore, Amer M. Zeidan et al.|Leukemia Research|2013Cited by 31